REFERENCES
- Mamo JG. The rate of visual loss in Behcet's disease. Archives of Ophthalmology 1970; 84: 451–452
- Yazici H, Pazarli H, Barnes C G, et al. A controlled trial of azathioprine in Behcet's syndrome. N Eng J Med 1990; 322: 281–285
- Masuda K, Nakajima A, Urayama A, Nakae K, Kogene M, Inaba G. Double masked trial of cyclosporin versus colchicine and long term open study of cyclosporin in Behcet's disease. Lancet 1989; 1: 1093
- Kotter I, Zierhut M, Eckstein A K, et al. Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003; 87: 423–431
- Sfikakis P P, Theodossiadis P G, Katsiari C G, Kaklamanis P, Markomichelakis N N. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001; 358: 295–296
- Nussenblatt R B, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial. Proceedings of the National Academy of Sciences of the United States of America 1999; 96: 7462–7466
- Papaliodis G N, Chu D, Foster C S. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 2003; 110: 786–789
- Nussenblatt R B, Peterson J S, Foster C S, et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: A multicenter noncomparative interventional case series. Ophthalmology 2005; 112: 764–770
- Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J.Rheumatol 2004; 31: 1362–1368